- World rank, 2022–2025
- #15,639 of 28,054 · #31,202 all time
- Rank in China
- #2,501 of 3,058
- Research works
- 134 ▲ 407% vs 2013–17
- Citations
- 1.8k 13.5 per fractional work
- Top-10% rate
- 18.4% record average 16.5%
- Open access
- 44% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 5.8×. Every wedge is a field page.
- Immunology and Microbiology 5.8×
- Biochemistry, Genetics and Molecular Biology 4.0×
- Medicine 2.4×
- Nursing 1.9×
- Veterinary 1.2×
- Pharmacology, Toxicology and Pharmaceutics 1.1×
- Chemistry 0.9×
- Agricultural and Biological Sciences 0.8×
- Mathematics 0.7×
- Neuroscience 0.6×
- Dentistry 0.5×
- Engineering 0.5×
- Environmental Science 0.5×
- Materials Science 0.5×
- Health Professions 0.4×
- Economics, Econometrics and Finance 0.4×
- Chemical Engineering 0.3×
- Computer Science 0.3×
- Earth and Planetary Sciences 0.2×
- Energy 0.1×
- Business, Management and Accounting 0.1×
- Social Sciences 0.0×
Which keywords describe research at Fosun Pharma (China)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Cancer Therapy, Cancer, Inflammation, Breast Cancer, Tumor Microenvironment, Gene Therapy, Chemotherapy and Epidemiology.
- Macular Degeneration
- Therapeutic Targets
- Palbociclib
- Glycosylation
- Vaccine
- Therapy
- PARP Inhibitors
- Homologous Recombination
- DNA Repair
- Transcriptional Regulation
- Cancer Immunotherapy
- Metabolism
- Clinical Trials
- Monoclonal Antibody
- Innate Immunity
- Gene Therapy
- Immunotherapy
- Oxidative Stress
- Cancer Therapy
- Epidemiology
- Cancer
- Inflammation
- Breast Cancer
- Chemotherapy
- Tumor Microenvironment
- Cell Death
- Immune Response
- Prognostic Factors
- Immunity
- Metastatic Breast Cancer
- Synthetic Lethality
- BRCA Mutation
- HER2
- Inflammatory Diseases
- Targeted Therapy
- Trastuzumab
- Cell Cycle Control
- CDK4/6 Inhibitors
- Signal Transduction
- Lymphoma
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Cancer5▲ 5.4×26 topics
- Epidemiology5▲ 1.77×32 topics
- Inflammation5▲ 3.3×30 topics
- Cancer Therapy4▲ 11×11 topics
- Breast Cancer3▲ 19×5 topics
- Oxidative Stress3▲ 2.6×20 topics
- Chemotherapy3▲ 5.5×9 topics
- Immunotherapy3▲ 5.2×9 topics
- Tumor Microenvironment3▲ 8.5×6 topics
- Gene Therapy2▲ 18×6 topics
- Cell Death2▲ 12×4 topics
- Innate Immunity2▲ 8.5×7 topics
- Immune Response2▲ 4.5×7 topics
- Monoclonal Antibody2▲ 48×2 topics
- Prognostic Factors2▲ 6.0×9 topics
- Clinical Trials2▲ 3.6×6 topics
- Immunity2▲ 5.9×5 topics
- Metabolism2▲ 4.8×8 topics
- Metastatic Breast Cancer2▲ 44×2 topics
- Cancer Immunotherapy2▲ 15×3 topics
- Synthetic Lethality2▲ 69×2 topics
- Transcriptional Regulation2▲ 14×4 topics
- BRCA Mutation1▲ 89×1 topic
- DNA Repair1▲ 70×2 topics
- HER21▲ 71×1 topic
- Homologous Recombination1▲ 46×2 topics
- Inflammatory Diseases1▲ 11×5 topics
- PARP Inhibitors1▲ 89×1 topic
- Targeted Therapy1▲ 9.0×4 topics
- Therapy1▲ 10×3 topics
- Trastuzumab1▲ 45×1 topic
- Vaccine1▲ 5.1×5 topics
- Cell Cycle Control1▲ 63×2 topics
- Glycosylation1▲ 17×3 topics
- CDK4/6 Inhibitors1▲ 67×1 topic
- Palbociclib1▲ 67×1 topic
- Signal Transduction1▲ 12×4 topics
- Therapeutic Targets1▲ 11×5 topics
- Lymphoma1▲ 10×2 topics
- Macular Degeneration1▲ 13×3 topics
Which research topics does Fosun Pharma (China) publish most on?
By volume in 2022–2025: HER2/EGFR in Cancer Research, PARP inhibition in cancer therapy, Advanced Breast Cancer Therapies and Cancer Immunotherapy and Biomarkers.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 HER2/EGFR in Cancer Research Oncology 1 works
- 2 PARP inhibition in cancer therapy Oncology 1 works
- 3 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 1 works
- 4 Cancer Immunotherapy and Biomarkers Oncology 1 works
- 5 CAR-T cell therapy research Oncology 1 works
- 6 Protein Degradation and Inhibitors Molecular Biology 1 works
- 7 Peptidase Inhibition and Analysis Oncology 1 works
- 8 Fibroblast Growth Factor Research Molecular Biology 1 works
- 9 Melanoma and MAPK Pathways Molecular Biology 1 works
- 10 RNA Interference and Gene Delivery Molecular Biology 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Fosun Pharma (China)'s research output changed?
Output in 2018–2022 was 407% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Shanghai
- Shanghai Jiao Tong University
- Tongji University
- Fudan University
- Shanghai University
- East China Normal University
- East China University of Science and Technology
- Donghua University
- University of Shanghai for Science and Technology
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.